primary studies published RCT A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. Year: 2002 Date: 2002 Author: Ledson MJ Source J Aerosol Med. 2002 Spring;15(1):51-7. Study design (if review, criteria of inclusion for studies) Single centre, RCT, double-blind, placebo controlled, cross-over design, 4 weeks. Participants Diagnosed CF in a stable clinical state infected with B. cepacia. 20 participants. Age, mean 23.6 (range 17 - 37) Interventions Nebulizer CR50, Ventstream at flow 6-7 L/min Inhaled 2% Taurolidine 4ml or 0.9% saline 4ml twice daily for 4 weeks, then cross-over with 2 week washout Outcome measures B. cepacia and P. aeruginosa colony counts. FEV1, FVC, symptom questionnaire. Main results There was no change in B. cepacia colony counts or spirometry, nor symptom scores. Authors' conclusions although taurolidine is well tolerated in nebulized form, in this study it had no in vivo anti-B. cepacia activity. Related topics General nutrition recommendations in cystic fibrosis